In the current study, diabetes significantly suppressed BDNF expression and p-CREB (S133) levels in the hippocampus, and PERK inhibitor had improved the BDNF expression and CREB activity, which were consistent with those in FGF1 treatment group. The gene discussed is CREB1; the disease is diabetes mellitus.